1-8 of 8
Christopher J. Forlenza
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Pembrolizumab (pembro) in Children and Young Adults with Low-Risk Classical Hodgkin Lymphoma (cHL) with Slow Early Response (SER) to Front-Line Chemotherapy (chemo): Early Results from the Phase 2 Keynote-667 Study

Lisa Giulino Roth, Frank Keller, Mario Melgar Toledo, Sharon M. Castellino, Christopher J. Forlenza, Maitane Andión Catalan, Julie Krystal, Adam Lamble, Aarati V. Rao, Fabio Molina Morales, Stacy Cooper, Flavio Luisi, Oscar Gonzalez Llano, Karla Alejandra Lopez, Christine Mauz-Koerholz, Bradford Hoppe, Juan Shen, Pallavi Pillai, Patricia Marinello, Kara M. Kelly
Journal: Blood
Blood (2023) 142 (Supplement 1): 1700.
https://doi.org/10.1182/blood-2023-186719
Published: 2023
Journal Articles

Progression-Free Survival (PFS) and Toxicity with Nivolumab-AVD Compared to Brentuximab Vedotin-AVD in Pediatric Advanced Stage (AS) Classic Hodgkin Lymphoma (cHL), Results of SWOG S1826

Sharon M. Castellino, Hongli Li, Alex F. Herrera, Angela Punnett, Michael Leblanc, Susan K Parsons, David Hodgson, Frank Keller, Richard A. Drachtman, Adam Lamble, Christopher J. Forlenza, Andrew Doan, Sarah C. Rutherford, Andrew M Evens, Richard F. Little, Malcolm A. Smith, Joo Y Song, Sonali M. Smith, Jonathan W. Friedberg, Kara M. Kelly
Journal: Blood
Blood (2023) 142 (Supplement 1): 610.
https://doi.org/10.1182/blood-2023-180107
Published: 2023
Journal Articles

Results from an Intergroup Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Classic Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412)

Catherine S Diefenbach, Opeyemi Jegede, Stephen M Ansell, Christian Steidl, Yasodha Natkunam, David W. Scott, Neha Mehta-Shah, Jennifer E Amengual, Christopher J. Forlenza, Peter D. Cole, Nancy L. Bartlett, Kevin A. David, Ranjana H. Advani, Richard F. Ambinder, Sachdev Thomas, Sami Ibrahimi, Brad S. Kahl
Journal: Blood
Blood (2023) 142 (Supplement 1): 607.
https://doi.org/10.1182/blood-2023-184531
Published: 2023
Journal Articles

Brentuximab Vedotin As Consolidation Therapy Following Autologous Stem Cell Transplantation in Children and Adolescents with Relapsed/Refractory Hodgkin Lymphoma: A Multi-Center Retrospective Analysis

Christopher J. Forlenza, Jaclyn Rosenzweig, Audrey Mauguen, Ilia Buhtoiarov, Branko Cuglievan, Hema Dave, Rebecca J Deyell, Jaime Flerlage, Anna Franklin, Jennifer Krajewski, Kasey J Leger, Lianna Marks, Robin Norris, Martha Pacheco, Faye Willen, Adam Paul Yan, Paul Harker-Murray, Lisa Giulino Roth
Journal: Blood
Blood (2021) 138 (Supplement 1): 2465.
https://doi.org/10.1182/blood-2021-151808
Published: 2021
Journal Articles

Pediatric Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia Harboring Heterogeneous Genomic Profiles Respond to Venetoclax in Combination with Chemotherapy

Andrew E. Place, MDPhD, Seth E. Karol, MD, Christopher J. Forlenza, MD, Marion Gambart, MD, Todd M. Cooper, DO, Christopher Fraser, MBBS, Gunnar Cario, MD PhD, Maureen M O'Brien, MD, Nicolas U. Gerber, MD, Phillip Barnette, MD, Dirk Reinhardt, MDPhD, Giridharan Ramsingh, MD, Bo Tong, PhD, Kristina Unnebrink, PhD, Deeksha Vishwamitra, PhD, Fengjiao Dunbar, PhD, Betty A. Prine, BS, Tammy L. Palenski, PhD, Mignon L. Loh, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 37–38.
https://doi.org/10.1182/blood-2020-137376
Published: 2020
Journal Articles

Brentuximab Vedotin Plus Bendamustine for Pediatric Patients with Relapsed/Refractory Hodgkin Lymphoma: A Multi-Institution Retrospective Analysis

Christopher J. Forlenza, MD, Nitya Gulati, MBBS, Audrey Mauguen, PhD, Michael J. Absalon, Sharon M. Castellino, MD MSc, Anna Franklin, MD, Frank G. Keller, MD, Neal Shukla, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 35.
https://doi.org/10.1182/blood-2020-139480
Published: 2020
Journal Articles

Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL

Clinical Trials & Observations
Kevin J. Curran, Steven P. Margossian, Nancy A. Kernan, Lewis B. Silverman, David A. Williams, Neerav Shukla, Rachel Kobos, Christopher J. Forlenza, Peter Steinherz, Susan Prockop, Farid Boulad, Barbara Spitzer, Maria I. Cancio, Jaap Jan Boelens, Andrew L. Kung, Yasmin Khakoo, Victoria Szenes, Jae H. Park, Craig S. Sauter, Glenn Heller, Xiuyan Wang, Brigitte Senechal, Richard J. O’Reilly, Isabelle Riviere, Michel Sadelain, Renier J. Brentjens
Journal: Blood
Blood (2019) 134 (26): 2361–2368.
https://doi.org/10.1182/blood.2019001641
Published: 2019
Includes: Supplemental data
Journal Articles

Inotuzumab Ozogamicin Is an Effective Salvage Therapy in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia with High-Risk Molecular Features, Including TP53 Loss

Xiaochuan Yang, Amber C. King, PharmD, BCOP, Charlene C. Kabel, PharmD, Christopher J. Forlenza, MD, Jae H. Park, MD, Mark B. Geyer, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3888.
https://doi.org/10.1182/blood-2019-125165
Published: 2019